Inclusion Criteria:

1. Patients with non-Hodgkin's B-cell lymphoma (NHL) including follicular, large cell
and Mantle cell lymphoma will be included.

2. Patients in complete clinical remission and determined to have no evidence of active
disease (NED).

3. Patients greater than or equal to 18 years of age who have given informed consent and
signed the IRB approved informed consent.

4. Ambulatory, medically stable persons; community dwelling; able to give informed
consent and available for all study visits; able to understand and comply with
planned study procedures; ECOG performance status of less than or equal to 2.

5. Medically stable subjects may have underlying illnesses such as hypertension,
diabetes, ischemic heart disease, or hypothyroidism, but their symptoms/signs are
controlled with medical therapy.

6. Patients with a non-metastatic secondary solid tumor or malignancies not currently (<
3 months) being treated will be included.

Exclusion Criteria:

1. Patients with Hodgkin's disease, and T-cell lymphoma.

2. Patients undergoing antineoplastic therapy.

3. Patients who have received chemotherapy within the past 3 months.

4. Individuals who were given rituximab (ibritumomab tiuxetan) in < 6 months.

5. Patients receiving systemic corticosteroids and/or high-dose inhaled steroids (>800
mcg per day of beclomethasone dipropionate or equivalent).

6. Splenectomized individuals will not be included.

7. Known allergy to eggs or other components of vaccine (e.g., thimerosal).

8. Acute or chronic condition that (in the opinion of the investigator) would render
vaccination unsafe or would interfere with the evaluation of responses (including but
not limited to the following: acute febrile illness, known chronic liver disease;
significant renal disease; oxygen-dependent chronic lung disease, New York Heart
Association Functional Class III or IV dyspnea; unstable or progressive neurologic
disorder; insulin-dependent diabetes mellitus).

9. Concomitant use of investigational vaccines and/or other medications within 4 weeks
prior to study entry, or expected use of experimental or licensed vaccines or
blood/blood products prior to study completion.

10. Previous exposure to parenteral immunoglobulins or other blood product within 6
months prior to enrollment into the study.

11. Subject is enrolled in a conflicting clinical trial.

12. Use of experimental vaccines or medications within one month of study entry.

13. Any acute or chronic condition which in the opinion of the investigator would render
vaccination unsafe or interfere with the evaluation of response.

14. Patients with a known history or risk factors (IV drug abuse or casual sex within the
past year) of Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus.